In This Section

Regulatory Science and Policy

The AACR supports the U.S Food and Drug Administration’s (FDA’s) efforts to modernize the regulatory process and accommodate the fast pace of innovation in science and technology by facilitating scientific exchange among stakeholders from academia, industry, advocacy, and government. With guidance and insight from the Regulatory Science and Policy Subcommittee of the Science Policy and Government Affairs Committee, the AACR actively engages in the development and implementation of programmatic and policy initiatives to improve the development, evaluation, and regulation of cancer drugs, biologics, and devices.

Regulatory Science and Policy initiatives include:

Regulatory Science and Policy Events: The AACR works closely with the FDA and other organizations to hold workshops on topics relevant to AACR members and FDA regulators.

Regulatory Science and Policy Track: A major track at the AACR Annual Meeting provides attendees with opportunities to interact with regulators, industry experts, and academics, including basic researchers and physician scientists. The informative sessions that make up this track are designed to highlight recent regulatory developments and provide an open forum for the discussion of cutting-edge issues in cancer drug, biologic, and diagnostic regulation.

Project Livin’ Label is an educational initiative in collaboration with the FDA that aims to foster broad understanding of the associated oncology product label and increase awareness of recent oncology drug FDA approvals in the cancer community through on-demand videos.

AACR Science Series at the FDA: This series of lectures brings scientific leaders to the FDA campus to present cutting-edge advances in cancer biology to FDA scientific review staff.

FDA-AACR Oncology Educational Fellowship: This fellowship is designed to promote scientific progress through exchange of scientific knowledge in oncology education, collaborative learning, and research.

Policy Positions and Documents